150 related articles for article (PubMed ID: 15851910)
1. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
J Acquir Immune Defic Syndr; 2005 May; 39(1):23-31. PubMed ID: 15851910
[TBL] [Abstract][Full Text] [Related]
2. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.
Lawn SD; Myer L; Bangani N; Vogt M; Wood R
BMC Infect Dis; 2007 May; 7():41. PubMed ID: 17509133
[TBL] [Abstract][Full Text] [Related]
5. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J
Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.
Schneider UV; Nielsen RL; Pedersen C; Eugen-Olsen J
BMC Infect Dis; 2007 Nov; 7():134. PubMed ID: 18021410
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients.
Ostrowski SR; Katzenstein TL; Piironen T; Gerstoft J; Pedersen BK; Ullum H
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):337-42. PubMed ID: 15097149
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
9. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau.
Jaffar S; Van der Loeff MS; Eugen-Olsen J; Vincent T; Sarje-Njie R; Ngom P; Meyer AM; Berry N; Aaby P; Whittle H
AIDS Res Hum Retroviruses; 2005 Jun; 21(6):560-4. PubMed ID: 15989461
[TBL] [Abstract][Full Text] [Related]
10. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
Fernebro E; Madsen RR; Fernö M; Brünner N; Bendahl P; Christensen IJ; Johnson A; Nilbert M
Eur J Cancer; 2001 Mar; 37(4):486-91. PubMed ID: 11267858
[TBL] [Abstract][Full Text] [Related]
12. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
13. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.
Eugen-Olsen J; Gustafson P; Sidenius N; Fischer TK; Parner J; Aaby P; Gomes VF; Lisse I
Int J Tuberc Lung Dis; 2002 Aug; 6(8):686-92. PubMed ID: 12150480
[TBL] [Abstract][Full Text] [Related]
14. Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.
Kirkegaard-Klitbo DM; Langkilde A; Mejer N; Andersen O; Eugen-Olsen J; Benfield T
J Infect Dis; 2017 Oct; 216(7):819-823. PubMed ID: 29099961
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.
Ostrowski SR; Ullum H; Goka BQ; Høyer-Hansen G; Obeng-Adjei G; Pedersen BK; Akanmori BD; Kurtzhals JA
J Infect Dis; 2005 Apr; 191(8):1331-41. PubMed ID: 15776381
[TBL] [Abstract][Full Text] [Related]
16. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
[TBL] [Abstract][Full Text] [Related]
17. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
20. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
Rasmussen LJ; Knudsen A; Katzenstein TL; Gerstoft J; Obel N; Jørgensen NR; Kronborg G; Benfield T; Kjaer A; Eugen-Olsen J; Lebech AM
HIV Med; 2016 May; 17(5):350-7. PubMed ID: 26365671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
